7.03
-0.05
(-0.71%)
Real-time:
2:25PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 6.96 - 7.10 |
| 52 week | 6.65 - 10.63 |
| Open | 7.10 |
| Vol / Avg. | 8,318.00/56,073.00 |
| Mkt cap | 187.19M |
| P/E | - |
| Div/yield | - |
| EPS | -4.36 |
| Shares | 26.63M |
| Beta | - |
| Inst. own | 66% |
Events
Jul 8, 2013
Q2 2013 Durata Therapeutics Inc Earnings Release
Jun 5, 2013
Durata Therapeutics Inc at Jefferies Global Healthcare Conference
May 16, 2013
Durata Therapeutics Inc Annual Shareholder Meeting
May 14, 2013
Durata Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 9, 2013
Q1 2013 Durata Therapeutics Inc Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -73.25% | -104.08% |
| Return on average equity | -173.22% | -255.57% |
| Employees | 38 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 2550, 200 South Wacker Drive
CHICAGO, IL 60606
United States - Map
+1-312-2197000 (Phone)
+1-302-6555049 (Fax)
CHICAGO, IL 60606
United States - Map
+1-312-2197000 (Phone)
+1-302-6555049 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Volume delayed by 15 mins.
Advertisement
Description
Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia.As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.
Officers and directors
| Richard U. De Schutter | Independent Chairman of the Board | |
| Paul R. Edick | Chief Executive Officer, Director | |
| Corey N. Fishman | Chief Financial Officer, Chief Operating Officer | |
| Michael W. Dunne M.D. | Chief Medical Officer | |
| John Shannon | Chief Commercial Officer | |
| Brenton K. Ahrens MBA | Independent Director | |
| Lisa Giles | Independent Director | |
| Dov A. Goldstein M.D. | Independent Director | |
| James I. Healy M.D., Ph.D. | Independent Director | |
| Ronald M. Hunt mba | Independent Director |